amgen

NovaSeq platform was debuted in January with a goal of lowering the cost of sequencing a human genome to $100. Illumina is expecting strong demand for this platform, which helped the firm to raise its outlook for the year. Check out the earnings highlights: https://alphastreet.com/bite/3af2cd8